Alphamab Oncology enrols patients for KN026-203 phase 2 clinical trial
Alphamab Oncology said that it has completed enrolling patients in China for its KN026-203 phase 2 clinical trial of the combination of KN026 and KN046 in the treatment of HER2-positive solid tumors.
While KN026 is a HER2 bispecific antibody developed by the Chinese clinical-stage biopharma company, KN046 is a PD-L1/CTLA-4 bispecific antibody, developed by Jiangsu Alphamab.
Alphamab Oncology expects to release an interim analysis of the KN026-203 phase 2 clinical trial in Q2 2022.
According to Alphamab Oncology, KN026-203 is an open-label study to be held across 25 centers in China for assessing the efficacy and safety of the KN026, KN046 combo in 102 patients with HER2-positive GC/GEJ, breast cancer and other HER2-positive solid tumors.
Alphamab Oncology enrols patients for KN026-203 phase 2 clinical trial of KN026 and KN046 combo in HER2-positive solid tumors. Image courtesy of doodlartdotcom from Pixabay.
Professor Shen Lin from Peking University Cancer Hospital, the principal investigator of the KN026-203 clinical trial, said: “Over expression of HER2 occurs in multiple tumor types such as breast, gastric, and intestinal cancers. There are urgent needs to develop effective treatment for those tumors.
“A number of preclinical and clinical studies have shown the potential efficacy of anti-HER2 therapy in combination with immunotherapy. Combination of KN026 and KN046 is a exploration with global edge and potential to change treatment landscape forHER2-positive tumor. We are looking forward the data from interim analysis to confirming clinical value of the combo.”